Fate Therapeutics, Inc.
FATE
$1.00
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.39% | 7.46% | -15.74% | -2.92% | 16.94% |
| Total Depreciation and Amortization | -16.36% | -7.60% | 3.72% | 4.36% | 14.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -100.00% |
| Total Other Non-Cash Items | 67.93% | 60.86% | 389.99% | 308.22% | 551.56% |
| Change in Net Operating Assets | 59.94% | -203.94% | -110.21% | 53.81% | -370.28% |
| Cash from Operations | 17.75% | 9.81% | 7.10% | 22.98% | 25.15% |
| Capital Expenditure | -256.85% | 39.29% | 88.14% | 93.57% | 95.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 224.65% | -68.13% | -89.10% | -73.27% | -82.22% |
| Cash from Investing | 224.18% | -68.85% | -89.16% | -71.14% | -80.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | 28,387.55% | 4,136.36% | 2,209.33% |
| Repurchase of Common Stock | -- | -270.00% | -270.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -79.69% | -74.64% | -- | -- | -- |
| Cash from Financing | -95.39% | -95.38% | 117,420.00% | 5,319.87% | 2,854.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.75% | -202.65% | 44.84% | 99.23% | -15.98% |